ATARAX SYRUP 10mg/5ml FOR ORAL USE

Product Information

Registration Status: Active

ATARAX SYRUP 10mg/5ml is approved to be sold in Singapore with effective from 1988-04-30. It is marketed by GLAXOSMITHKLINE PTE LTD, with the registration number of SIN00570P.

This product contains Hydroxyzine 10mg/5ml in the form of SYRUP. It is approved for ORAL use.

This product is manufactured by NEXTPHARMA SAS in FRANCE.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Description

A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite cetirizine, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative. [PubChem]

Indication

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria.

Mechanism of Action

Hydroxyzine competes with histamine for binding at H₁-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The sedative properties of hydroxyzine occur at the subcortical level of the CNS. Secondary to its central anticholinergic actions, hydroxyzine may be effective as an antiemetic.

Pharmacokinetics

Absorption: Rapidly absorbed from the gastrointestinal tract
Distribution
Metabolism: Hepatic
Elimination

Toxicity

Oral, rat LD₅₀: 950 mg/kg. Symptoms of overexposure include hypersedation.

Active Ingredient/Synonyms

Source of information: Drugbank (External Link). Last updated on: 3^rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.